Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | PKM | P14618 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | VEGFA | P15692 | 1/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3202921 | 1.00 | ALDH1A1 (0.37) | ALDH1A1PKMPOLBMMP2HTT | |
| SCHEMBL6329164 | 0.85 | ALDH1A1 (0.42) | ALDH1A1POLBRAPGEF4L3MBTL1GAA | |
| SCHEMBL13422055 | 0.85 | ALDH1A1 (0.42) | ALDH1A1POLBRAPGEF4L3MBTL1GAA | |
| SCHEMBL3213248 | 0.78 | MMP2 (0.46) | ALDH1A1PKMPOLBMMP2HTT | |
| SCHEMBL26980233 | 0.77 | PKM (0.42) | ALDH1A1PKMPOLBMMP2HTT | |
| SCHEMBL6605034 | 0.72 | KMT2A (0.51) | — | |
| SCHEMBL6605044 | 0.72 | KMT2A (0.51) | — | |
| SCHEMBL20780052 | 0.71 | PKM (0.46) | ALDH1A1PKMPOLBMMP2HTT | |
| SCHEMBL21084617 | 0.70 | ACHE (0.41) | ALDH1A1PKMPOLBMMP2HTT | |
| SCHEMBL6320420 | 0.68 | VEGFA (0.40) | ALDH1A1VEGFAEGLN1RAPGEF4ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7671079-B2 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH LLC (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2008-04-10 | — | — | US | disclosed |
| US-7288561-B2 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2007-10-30 | — | — | US | disclosed |
| EP-1682502-A1 | SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005047252-A1 | SULFONYLTETRAHYDRO-3H-BENZO(E)INDOLE-8-AMINE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20050101596-A1 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands | WYETH (US) | 2005-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085925-A1 | Sulfonyltetrahydro-3H-benzo(e)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | ALDH1A1 1192/4885PKM 3353/4885POLB 4840/4885 |
| US-20050101596-A1 | Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-Hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | ALDH1A1 1192/4885PKM 3353/4885POLB 4840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.